CRDF vs IMVT vs PRAX vs CRL

For growth investors, Charles River Laboratories International, Inc.

(CRL) is the stronger pick with -0. 9% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Cardiff Oncology, Inc. (CRDF) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +207. 0%, compared to -79. 8% for Cardiff Oncology, Inc. (CRDF). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus CRDF's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Charles River Laboratories International, Inc.

(CRL) is the lower-risk stock at 1. 39β versus Cardiff Oncology, Inc. 's 2. 23β — meaning CRDF is approximately 61% more volatile than CRL relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Charles River Laboratories International, Inc.

(CRL) is pulling ahead at -0. 9% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Cardiff Oncology, Inc. grew EPS 27. 4% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, CRDF leads at 15. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Immunovant, Inc.

(IMVT) is the more profitable company, earning 0. 0% net margin versus -77. 3% for Cardiff Oncology, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus -82. 6% for CRDF. At the gross margin level — before operating expenses — CRDF leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRAX: 144.

8% to $607. 15.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Charles River Laboratories International, Inc.

(CRL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+122. 4% 10Y return). Cardiff Oncology, Inc. (CRDF) carries a higher beta of 2. 23 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRL: +122. 4%, CRDF: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.